There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .
Circulating visfatin levels in healthy preterm infants are independently associated with high-density lipoprotein cholesterol levels and dietary long-chain polyunsaturated fatty acids.
The adipokine visfatin has been proposed to exert insulin-mimicking effects and to play a role in the development of metabolic syndrome . Preterm infants are at risk for the later development of insulin resistance and , possibly , for other components of metabolic syndrome . Dietary long-chain polyunsaturated fatty acids ( LCPUFAs ) during the perinatal period may reduce the risk of metabolic syndrome . The authors ' objective was to study the circulating concentrations of visfatin in preterm infants and to examine associations of visfatin with anthropometric measurements , metabolic indices , and dietary LCPUFAs . Serum visfatin concentrations were determined by enzyme-linked immunosorbent assay at mean ( SD ) 33.8 ( 11.7 ) days of life in 60 healthy preterm infants ( gestational age , 32.7 [ 1.9 ] weeks ) r and omly assigned to be fed since birth either a formula containing LCPUFA ( arachidonic and docosahexaenoic acid ) ( + LCPUFA group ) or the same formula without LCPUFA ( -LCPUFA group ) . Associations of visfatin with anthropometric parameters , serum glucose , insulin , homeostasis model assessment index of insulin resistance , blood lipids , and adiponectin levels were examined . Serum visfatin levels were significantly higher in the + LCPUFA than in the -LCPUFA group ( P < .001 ) and correlated positively with body weight z score ( β = 0.31 , P = .02 ) , total cholesterol ( β = 0.34 , P = .01 ) , high-density lipoprotein cholesterol ( HDL-C ) ( β = 0.47 , P < .001 ) , and adiponectin levels ( β = 0.29 , P = .03 ) , but not with indices of insulin sensitivity . In multiple regression analysis , HDL-C and dietary LCPUFAs correlated independently with serum visfatin levels . Circulating visfatin levels in preterm infants are independently associated with HDL-C levels and dietary LCPUFAs . Whether the higher visfatin levels in the + LCPUFA preterm infant group are beneficial for the later health of these infants remains to be determined
There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy , asthma , dermatitis/eczema or food allergy .
However , the quality of evidence was very low .
There was insufficient evidence to determine an effect on allergic rhinitis
BACKGROUND Early dietary intakes may influence the development of allergic disease .
It is important to determine if dietary polyunsaturated fatty acids ( PUFAs ) given as supplements or added to infant formula prevent the development of allergy .
OBJECTIVES To determine the effect of higher PUFA intake during infancy to prevent allergic disease .